Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing numbe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ro, Jungsil, Cheng, Fiona Tsui-Fen, Sriuranpong, Virote, Villalon, Antonio, Smruti, B. K, Tsang, Janice, Yap, Yoon Sim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822111/
https://www.ncbi.nlm.nih.gov/pubmed/27066091
http://dx.doi.org/10.4048/jbc.2016.19.1.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822111/
https://www.ncbi.nlm.nih.gov/pubmed/27066091
http://dx.doi.org/10.4048/jbc.2016.19.1.8

Ejemplares similares